Dynavax Technologies Corporation (NASDAQ:DVAX) total revenues for the year ended December 31, 2013, increased by $1.5 million, or 16%, as compared to the same period in 2012 principally due to an increase in grant revenue. Dynavax Technologies Corporation (NASDAQ:DVAX) shares after opening at $1.59 moved to $1.60 on last trade day and at the end of the day closed at $1.50. Company price to sales ratio in past twelve months was calculated as 34.90 and price to cash ratio as 2.08. Dynavax Technologies Corporation (NASDAQ:DVAX) showed a negative weekly performance of -6.83%.
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 20,400 shares of the stock on the open market in a transaction that occurred on Thursday, April 10th. The stock was purchased at an average price of $9.28 per share, with a total value of $189,312.00. Following the completion of the transaction, the chief executive officer now directly owns 1,987,500 shares of the company’s stock, valued at approximately $18,444,000. Opko Health Inc. (NYSE:OPK) shares fell -5.64% in last trading session and ended the day on $8.37. OPK return on equity ratio is recorded as -19.30% and its return on assets is -11.30%. Opko Health Inc. (NYSE:OPK) yearly performance is 20.61%.
Cel-Sci Corporation (NYSEMKT:CVM) saw its stock plunge after pricing a public offering of over 7 million shares of stock. Pricing the units at $1.40 apiece for gross proceeds of $10 million. CEL-SCI Corporation (NYSEMKT:CVM) shares moved down -13.24% in last trading session and was closed at $1.31, while trading in range of $1.27 – $1.41. CEL-SCI Corporation (NYSEMKT:CVM) year to date (YTD) performance is 122.03%.
Zogenix, Inc. (NASDAQ:ZGNX) filed a lawsuit in the U.S. District Court in Massachusetts requesting the court to grant a temporary restraining order against execution of the executive order recently announced by Governor Deval Patrick, which prohibits the prescribing and dispensing of the Company’s prescription pain product that was approved by the U.S. Food and Drug Administration (FDA). Zogenix, Inc. (NASDAQ:ZGNX) weekly performance is -0.41%. On last trading day company shares ended up $2.45. Zogenix, Inc. (NASDAQ:ZGNX) distance from 50-day simple moving average (SMA50) is -35.55%. Analysts mean target price for the company is $5.73.